Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 2/2015

01-02-2015 | Original Article

Predictive Factors Analysis for Malignant Peritoneal Mesothelioma

Authors: Shi Jin, Shoubo Cao, Jingyan Cao, Jing Shen, Jing Hu, Dehai Che, Jiawen Zhang, Yan Yu

Published in: Journal of Gastrointestinal Surgery | Issue 2/2015

Login to get access

Abstract

Background

Malignant peritoneal mesothelioma (MPM) is an uncommon disease with a dismal prognosis and unclear natural history. The present study aims to assess potential prognostic factors and management of MPM.

Methods

Clinical records of 39 patients with MPM between December 2003 and April 2014 were retrospectively reviewed. Overall survival was identified with Kaplan-Meier curves and Cox regression analysis.

Results

Mean age of 39 patients was 55.0 years; asbestos exposure was recorded in two patients. Main presentations were abdominal distension, abdominal pain, and weight loss. Thrombocytosis, low serum albumin level, and anemia were principal laboratory abnormalities. Ascites, peritoneal cavity mass, and peritoneum thickening were the main signs on CT scans. Cytoreductive surgery (CRS) plus adjuvant therapies were performed in 22 patients, single chemotherapy in 13, and best supportive care in 4. Median survival time was 10.0 months after pathological diagnosis, with a 6-, 12-, 18-, and 24-month survival rate of 84.4, 31.6, 18.5, and 15.8 %, respectively. Significant prognostic factors were age, performance status (PS), abdominal pain, serum albumin level, thrombocytosis, and treatment strategy on univariate analysis, while only age, abdominal pain, and treatment strategy hold statistical significance on multivariate analysis.

Conclusions

Age ≤65 years, abdominal pain, and CRS plus adjuvant therapy are independent positive prognostic factors of MPM.
Literature
2.
3.
go back to reference Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer 2008;61:235–243.PubMedCrossRef Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer 2008;61:235–243.PubMedCrossRef
4.
go back to reference Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. EJSO 2006;32:676–681.PubMedCrossRef Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. EJSO 2006;32:676–681.PubMedCrossRef
6.
go back to reference Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–1593.PubMedCrossRef Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–1593.PubMedCrossRef
8.
go back to reference Cunha P, Luz Z, Seves I, Sousa C, Skiappa, Ribeiro L, Marques C, Oliveira M. Malignant peritoneal mesothelioma-diagnostic and therapeutic difficulties. Acta Med Port 2002;15:383–386.PubMed Cunha P, Luz Z, Seves I, Sousa C, Skiappa, Ribeiro L, Marques C, Oliveira M. Malignant peritoneal mesothelioma-diagnostic and therapeutic difficulties. Acta Med Port 2002;15:383–386.PubMed
9.
go back to reference Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol 2011;35:55–59.PubMedCrossRef Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol 2011;35:55–59.PubMedCrossRef
10.
go back to reference Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell’Erba D. Primary diffuse malignant peritoneal mesothelioma: case report and update of therapy. J Surg Oncol 2000;75:55–58.PubMedCrossRef Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell’Erba D. Primary diffuse malignant peritoneal mesothelioma: case report and update of therapy. J Surg Oncol 2000;75:55–58.PubMedCrossRef
11.
go back to reference Tan GH, Cheung M, Chanyaputhipong J, Soo KC, Teo MC. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 2013;42:291–296.PubMed Tan GH, Cheung M, Chanyaputhipong J, Soo KC, Teo MC. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 2013;42:291–296.PubMed
12.
go back to reference Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma-an update on treatment. Cancer Treat Rev 2012;38:605–612.PubMedCrossRef Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma-an update on treatment. Cancer Treat Rev 2012;38:605–612.PubMedCrossRef
13.
go back to reference Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21:1159–1165.PubMedCrossRef Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21:1159–1165.PubMedCrossRef
14.
go back to reference Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–3148.PubMedCrossRef Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–3148.PubMedCrossRef
15.
go back to reference Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269–273.PubMed Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269–273.PubMed
16.
go back to reference Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012;40:185–189.PubMedCrossRef Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012;40:185–189.PubMedCrossRef
17.
go back to reference Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012;23:1494–1498.PubMedCrossRef Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012;23:1494–1498.PubMedCrossRef
18.
go back to reference Park JY, Kim KW, Kwon HJ, Park MS, Kwon GY, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 2008;191:814–825.PubMedCrossRef Park JY, Kim KW, Kwon HJ, Park MS, Kwon GY, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 2008;191:814–825.PubMedCrossRef
19.
go back to reference Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010;21:348–353.PubMedCrossRef Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010;21:348–353.PubMedCrossRef
20.
go back to reference Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013;100:285–292.PubMedCrossRef Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013;100:285–292.PubMedCrossRef
21.
go back to reference Wang J, Gao L, Tang S, Li T, Lei Y, Xie H, Liang J, Chen B, Wang X, Fan D. A retrospective analysis on the diagnostic value of ultrasound-guided percutaneous biopsy for peritoneal lesions. World J Surg Oncol 2013;11:251.PubMedCentralPubMedCrossRef Wang J, Gao L, Tang S, Li T, Lei Y, Xie H, Liang J, Chen B, Wang X, Fan D. A retrospective analysis on the diagnostic value of ultrasound-guided percutaneous biopsy for peritoneal lesions. World J Surg Oncol 2013;11:251.PubMedCentralPubMedCrossRef
22.
go back to reference Krasuski P, Poniecka A, Gal E. The diagnostic challenge of peritoneal mesothelioma. Arch Gynecol Obstet 2002;266:130–132.PubMedCrossRef Krasuski P, Poniecka A, Gal E. The diagnostic challenge of peritoneal mesothelioma. Arch Gynecol Obstet 2002;266:130–132.PubMedCrossRef
23.
go back to reference Chen LY, Huang LX, Wang J, Qian Y, Fang LZ. Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B 2011;12:381–384.PubMedCentralPubMedCrossRef Chen LY, Huang LX, Wang J, Qian Y, Fang LZ. Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B 2011;12:381–384.PubMedCentralPubMedCrossRef
25.
go back to reference Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012;10:49–57.PubMed Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012;10:49–57.PubMed
26.
go back to reference Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948–953.PubMedCrossRef Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948–953.PubMedCrossRef
27.
go back to reference Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–6242.PubMedCrossRef Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–6242.PubMedCrossRef
28.
go back to reference O’Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17:270–275.PubMedCrossRef O’Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17:270–275.PubMedCrossRef
29.
go back to reference Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008;26:3567–3572.PubMedCrossRef Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008;26:3567–3572.PubMedCrossRef
30.
go back to reference Cao SB, Jin S, Cao JY, Shen J, Zhang JW, Yu Y. Colonic invasion induced by malignant peritoneal mesothelioma. Int J Colorectal Dis 2014;29:891–892.PubMedCrossRef Cao SB, Jin S, Cao JY, Shen J, Zhang JW, Yu Y. Colonic invasion induced by malignant peritoneal mesothelioma. Int J Colorectal Dis 2014;29:891–892.PubMedCrossRef
Metadata
Title
Predictive Factors Analysis for Malignant Peritoneal Mesothelioma
Authors
Shi Jin
Shoubo Cao
Jingyan Cao
Jing Shen
Jing Hu
Dehai Che
Jiawen Zhang
Yan Yu
Publication date
01-02-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 2/2015
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-014-2664-4

Other articles of this Issue 2/2015

Journal of Gastrointestinal Surgery 2/2015 Go to the issue